The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
n–3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia
Open accessAbstract
BACKGROUND: The use of n-3 fatty acids may prevent cardiovascular events in patients with recent myocardial infarction or heart failure. Their effects in patients with (or at risk for) type 2 diabetes mellitus are unknown. METHODS: In this double-blind study with a 2-by-2 factorial design, we randomly assigned 12,536 patients who were at high risk for cardiovascular events and had impaired fasting glucose, impaired glucose tolerance, or diabetes to receive a 1-g capsule containing at least 900 mg (90% or more) of ethyl esters of n-3 fatty acids or placebo daily and to receive either insulin glargine or standard care. The primary outcome was death from cardiovascular causes. The results of the comparison between n-3 fatty acids and placebo are reported here. RESULTS: During a median follow up of 6.2 years, the incidence of the primary outcome was not significantly decreased among patients receiving n-3 fatty acids, as compared with those receiving placebo (574 patients [9.1%] vs. 581 patients [9.3%]; hazard ratio, 0.98; 95% confidence interval [CI], 0.87 to 1.10; P=0.72). The use of n-3 fatty acids also had no significant effect on the rates of major vascular events (1034 patients [16.5%] vs. 1017 patients [16.3%]; hazard ratio, 1.01; 95% CI, 0.93 to 1.10; P=0.81), death from any cause (951 [15.1%] vs. 964 [15.4%]; hazard ratio, 0.98; 95% CI, 0.89 to 1.07; P=0.63), or death from arrhythmia (288 [4.6%] vs. 259 [4.1%]; hazard ratio, 1.10; 95% CI, 0.93 to 1.30; P=0.26). Triglyceride levels were reduced by 14.5 mg per deciliter (0.16 mmol per liter) more among patients receiving n-3 fatty acids than among those receiving placebo (P<0.001), without a significant effect on other lipids. Adverse effects were similar in the two groups. CONCLUSIONS: Daily supplementation with 1 g of n-3 fatty acids did not reduce the rate of cardiovascular events in patients at high risk for cardiovascular events. (Funded by Sanofi; ORIGIN ClinicalTrials.gov number, NCT00069784.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Even among omega‐3 fatty acid studies, there are marked differences with respect to the relatively low doses of omega‐3 administered and the ratio of EPA to DHA.16, 17, 18, 19, 20, 21, 22, 23, 24”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the ORIGIN trial, which enrolled more than 12,000 patients with impaired fasting glucose and at high risk for cardiovascular events, the administration of 1 g/day of combined EPA + DHA (465 mg of EPA and 375 mg of DHA) had no impact on cardiovascular mortality [89].”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [89]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, many previous 20 , 21 , 22 , 23 and recently completed clinical studies 24 , 25 showed that ω3 PUFA supplementation did not offer significant favorable impacts on cardiovascular events.”
From Association Between Omega-3 Fatty Acid Intake and Dyslipidemia: A Continuous Dose-Response Meta-Analysis of Randomized Controlled Trials (2023) · cites this paper as [20]
The cited source says what the claim attributes to it.
In the citing paper
“The STRENGTH, VITAL, ASCEND, ORIGIN, OMEGA, ALPHA-OMEGA, GISSI-HF and GISSI-P trials randomized patients to receive either a combination of EPA and DHA or placebo; yet only the GISSI trials noted a statistically significant effect on cardiovascular events and mortality [96–103].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [99]
The cited source says what the claim attributes to it.
In the citing paper
“but subsequent larger trials failed to replicate these findings. 8,9”
From Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk (2020) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“Nevertheless, the dosage used in OMEMI was about twice that used in comparable earlier trials 5, 7, 23, 30 , although considerably lower than the dosage used in REDUCE-IT 14 , and also in the STRENGTH trial 36 .”
From Effects of n-3 Fatty Acid Supplements in Elderly Patients After Myocardial Infarction (2021) · cites this paper as [30]
The cited source says what the claim attributes to it.
In the citing paper
“A limitation to the study is the inclusion rate of 26 % of screened candidates, which is relatively low compared to other n-3 PUFA trials not targeting elderly patients 30-33 .”
From Effects of n-3 Fatty Acid Supplements in Elderly Patients After Myocardial Infarction (2021) · cites this paper as [30]
The cited source says what the claim attributes to it.
In the citing paper
“Other more recent omega‐3 therapy outcome studies conducted in the presence of statins have been less encouraging, but these studies were characterized by evaluating nonhypertriglyceridemic patient populations (eg, TG <200 mg/dL) and administering low doses of long‐chain omega‐3 fatty acids (eg, eicosapentaenoic acid [EPA] and/or docosoahexaenoic acid [DHA]).19, 20, 21, 22, 23, 24”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [21]
The cited source says what the claim attributes to it.
In the citing paper
“Our initial manuscript included Trials such as ORIGIN8, ASCEND9, Alpha Omega10, and JELIS5; among these trials, only one trial had IPE, and the rest of the trials had a combination of EPA and DHA, so our results were skewed as search strategy missed significant studies.”
From Cardiovascular outcomes and coronary artery disease prevention secondary to icosapent ethyl: a meta-analysis of randomized clinical trials (2024) · cites this paper as [8]
In the citing paper
“Data from studies on supplementation with n-3 fatty acids do not support recommending n-3 fatty acid supplements for secondary prevention of CVD in T2DM.86,87”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [86]
In the citing paper
“In the ORIGIN (Outcome Reduction With Initial Glargine Intervention) trial, 12 537 patients (mean age 63.5 years) at high CVD risk with impaired fasting glucose (IFG), impaired glucose tolerance (IGT), or T2DM were randomized to insulin glargine titrated to a fasting blood glucose level of ≤5.3 mmol/L (≤95 mg/dL) or standard care.86 After a median follow-up of 6.2 years, the incidence of CV”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [86]
In the citing paper
“The JELIS study692) conducted in Japan found that the addition of EPA to statins showed a significant preventive effect on major cardiovascular events compared to statin monotherapy.”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [692]
In the citing paper
“Evidence does not conclusively support recommending n-3 (eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA]) supplements for all people with diabetes for the prevention or treatment of cardiovascular events (70,209,210).”
From 5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes:Standards of Care in Diabetes—2023 (2023) · cites this paper as [210]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
Lichtenstein, A. H., Appel, L. J., Brands, M., Carnethon, M., Daniels, S., Franch, H. A., Franklin, B., Kris-Etherton, P., Harris, W. S., Howard, B., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.176158 · Cited by 2,705
(1999) · PubMed · Cited by 2,062
Basal insulin and cardiovascular and other outcomes in dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203858 · Cited by 1,636
Self-citationGISSI-HF investigators (2008) · The Lancet · doi:10.1016/s0140-6736(08)61239-8 · Cited by 1,350
Fish and Omega-3 Fatty Acid Intake and Risk of Coronary Heart Disease in Women
Hu, F. B. (2002) · JAMA · doi:10.1001/jama.287.14.1815 · Cited by 1,018
n–3 Fatty Acids and Cardiovascular Events after Myocardial Infarction
Kromhout, D., Giltay, E. J., & Geleijnse, J. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003603 · Cited by 936
n–3 Fatty acids and cardiovascular disease: evidence explained and mechanisms explored
Calder, P. C. (2004) · Clinical Science · doi:10.1042/cs20040119 · Cited by 571
Cardiovascular effects of marine omega-3 fatty acids
Saravanan, P., Davidson, N. C., Schmidt, E. B., & Calder, P. C. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60445-x · Cited by 513
Research works printed but not linked: 1
- Gerstein H, 2008, Am Heart J, 155, 26
Cited by
Sorted by citations
Items 501–600 of 933
Ng, T., Ooi, E. M. M., Watts, G. F., Chan, D. C., & Barrett, P. H. R. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12243 · Cited by 15
Mooradian, A. D., & Haas, M. J. (2014) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-014-0068-1 · Cited by 15
Beyond Statins: Lipid Management to Reduce Cardiovascular Risk
Schuck, R. N., Mendys, P., & Simpson, R. J. (2013) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1268 · Cited by 15
Fibrates and niacin: is there a place for them in clinical practice?
Wierzbicki, A. S., & Viljoen, A. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.972365 · Cited by 15
Triglyceride Treatment in the Age of Cholesterol Reduction
Agrawal, N., Corradi, P. F., Gumaste, N., & Goldberg, I. J. (2016) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2016.08.003 · Cited by 15
Baum, S. J., & Scholz, K. P. (2019) · Clinical Cardiology · doi:10.1002/clc.23220 · Cited by 15
Alter, P. J., Glück, T., Figiel, J. H., Koczulla, A. R., Vogelmeier, C. F., & Rupp, H. (2015) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2015.05.019 · Cited by 15
ω-3 fatty acids, γ-linolenic acid, and antioxidants: immunomodulators or inert dietary supplements?
Schott, C. K., & Huang, D. T. (2012) · Critical Care · doi:10.1186/cc11863 · Cited by 15
Spotlight on Icosapent Ethyl for Cardiovascular Risk Reduction: Evidence to Date
Jia, X., Koh, S., Al Rifai, M., Blumenthal, R. S., & Virani, S. S. (2020) · Vascular Health and Risk Management · doi:10.2147/vhrm.s210149 · Cited by 14
Kapoor, K., Alfaddagh, A., Stone, N. J., & Blumenthal, R. S. (2021) · Journal of clinical lipidology · doi:10.1016/j.jacl.2021.06.004 · Cited by 14
Xie, J., Wang, Z., Wang, J., Feng, W. Q., Shan, T., Jing, S., Xiao, S., Li, W. L., Liu, N., & Liu, Y. (2022) · Acta Diabetologica · doi:10.1007/s00592-022-02003-w · Cited by 14
Welty, F. K., Daher, R., & Garelnabi, M. (2023) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.122.318125 · Cited by 14
Bagge, A., Schött, U., & Kander, T. (2018) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365513.2018.1516477 · Cited by 14
Prado‐Cabrero, A., & Nolan, J. M. (2021) · AMBIO · doi:10.1007/s13280-020-01472-z · Cited by 14
Mszar, R., Bart, S., Sakers, A. P., Soffer, D. E., & Karalis, D. G. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041382 · Cited by 14
Omega-3 and Prostate Cancer: Examining the Pertinent Evidence
McCarty, M. F., DiNicolantonio, J. J., Lavie, C. J., & O’Keefe, J. H. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.10.029 · Cited by 14
The Year in Cardiology 2012: focus on cardiovascular disease prevention
Charakida, M., Masi, S., & Deanfield, J. E. (2013) · European Heart Journal · doi:10.1093/eurheartj/ehs429 · Cited by 14
The pro- or antiarrhythmic actions of polyunsaturated fatty acids and of cholesterol
Coronel, R. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.004 · Cited by 14
Ward, R. E., Cho, K., Nguyen, X. T., Vassy, J. L., Ho, Y.-L. A., Quaden, R. M., GAGNON, D. R., Wilson, P. W. F., Gaziano, J. M., & Djoussé, L. (2019) · Clinical Nutrition · doi:10.1016/j.clnu.2019.03.005 · Cited by 14
Xue, Q., Zhu, H., Ya, R., & Huang, H. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2401024 · Cited by 13
Current Drug Treatment of Hyperlipidemia in Older Adults
Dixon, D. L., Donohoe, K. L., Ogbonna, K. C., & Barden, S. M. (2015) · Drugs & Aging · doi:10.1007/s40266-015-0240-6 · Cited by 13
Bagepally, B. S., Chaikledkaew, U., Youngkong, S., Anothaisintawee, T., Thavorncharoensap, M., Dejthevaporn, C., & Thakkinstian, A. (2021) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s328433 · Cited by 13
Blood indices of omega-3 and omega-6 polyunsaturated fatty acids are altered in hyperglycemia
Alfhili, M. A., Alsughayyir, J., Basudan, A., Alfaifi, M. A., Awan, Z. A., Algethami, M. R., & Al‐Sheikh, Y. A. (2023) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2023.103577 · Cited by 13
Diagnostic accuracy of interferon gamma-induced protein 10 for tuberculosis: a meta-analysis.
Guo, S., Jia, L., Hu, Q.-J., Long, H.-Y., Pang, C., & Wen, F. (2014) · Europe PMC (PubMed Central) · Cited by 13
Umesawa, M., Yamagishi, K., & Iso, H. (2020) · European Journal of Clinical Nutrition · doi:10.1038/s41430-020-00751-y · Cited by 13
Dietary fatty acids and CHD: from specific recommendations to dietary patterns
Delarue, J. (2021) · Nutrition Research Reviews · doi:10.1017/s0954422420000293 · Cited by 13
Dietary fat composition and cardiac events in patients with type 2 diabetes
dos Santos, A. L. T., Weiss, T., Duarte, C. K., Gross, J. L., de Azevedo, M. J., & Zelmanovitz, T. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.06.014 · Cited by 13
n–3 Fatty Acids in Patients with Cardiac Risk Factors
Roncaglioni, M. C., Tombesi, M., & Silletta, M. G. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1308780 · Cited by 13
Rupp, T. P., Rupp, K. G., Alter, P., & Rupp, H. (2013) · Cardiology · doi:10.1159/000350656 · Cited by 12
Approach to Lipid Management in the Patient With Diabetes
Kim, S. J., & Subramanian, S. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf018 · Cited by 12
Song, X., Liu, H., Wang, X., Li, Z., & Huang, C. (2014) · Lipids in Health and Disease · doi:10.1186/1476-511x-13-186 · Cited by 12
McLennan, P. L., & Pepe, S. (2015) · Heart Lung and Circulation · doi:10.1016/j.hlc.2015.06.825 · Cited by 12
Peroxidized unsaturated fatty acids stimulate Toll-like receptor 4 signaling in endothelial cells
Mutoh, A., & Ueda, S. (2013) · Life Sciences · doi:10.1016/j.lfs.2013.03.019 · Cited by 12
Sekikawa, A. M., Willcox, B. J., Usui, T., Carr, J. J., Barinas‐Mitchell, E., Masaki, K., Watanabe, M., Tracy, R. P., Bertolet, M. H., Evans, R. G., et al. (2013) · Journal of Women s Health · doi:10.1089/jwh.2012.4087 · Cited by 12
Nutraceuticals for the treatment of metabolic diseases: evidence from clinical practice
Derosa, G., & Maffioli, P. (2014) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2015.995630 · Cited by 12
Sekikawa, A. M., Shin, C., Masaki, K., Barinas‐Mitchell, E., Hirooka, N., Willcox, B. J., Choo, J., White, J., Evans, R. W., Fujiyoshi, A., et al. (2013) · American Journal of Hypertension · doi:10.1093/ajh/hpt107 · Cited by 12
Basic Mechanisms of Atherosclerosis
Bäck, M., & Hansson, G. K. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-42880-4.00004-2 · Cited by 12
Tsuchiya, T., Endo, A., Tsujikado, K., & Inukai, T. (2017) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2017.06.002 · Cited by 12
Mechanisms underlying diabetic cardiomyopathy: From pathophysiology to novel therapeutic targets.
Cong, S., Ramachandra, C. J. A., Ja, K. P. M. M., Yap, J., SHIM, W. S. N., Wei, L., & Hausenloy, D. J. (2020) · PubMed · Cited by 13
Zang, T., Chen, H., Shen, S., Xu, F., Wang, R., Yin, J., Chen, X., Guan, M., Shen, L., Pan, H., et al. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/9451058 · Cited by 12
Fish Oil Selectively Improves Heart Function in a Mouse Model of Lipid-induced Cardiomyopathy
Khan, R. S., Chokshi, A. D., Drosatos, K., Jiang, H., Yu, S., Harris, C. R., Schulze, P. C., Homma, S., Blaner, W. S., Shulman, G. I., et al. (2013) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e318283d845 · Cited by 12
Dietary fatty acids in health and disease
Calder, P. C., & Deckelbaum, R. J. (2014) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000038 · Cited by 12
Mäntyselkä, P. T., NISKANEN, L. K., Kautiainen, H., Saltevo, J. T., Würtz, P., Soininen, P., Kangas, A. J., Ala‐Korpela, M., & Vanhala, M. J. (2014) · Lipids in Health and Disease · doi:10.1186/1476-511x-13-28 · Cited by 12
Kiage, J. N., Sampson, U. K. A., Lipworth, L. P., Fazio, S., Mensah, G. A., Yu, Q., Munro, H. M., Akwo, E. A., Dai, Q., Blot, W. J., et al. (2015) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2015.07.006 · Cited by 12
Detopoulou, P., & Antonopoulou, S. (2015) · Cited by 12
Reincarnated medicines: using out-dated drugs for novel indications
Ferrari, R., & Lüscher, T. F. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw051 · Cited by 12
From alga to omega; have we reached peak (fish) oil?
Clayton, P., & Ladi, S. (2015) · Journal of the Royal Society of Medicine · doi:10.1177/0141076815599673 · Cited by 12
Liu, X., Gong, M., & Wu, N. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1503704 · Cited by 11
Watanabe, T., Miyamoto, T., Miyasita, T., Shishido, T., Arimoto, T., Takahashi, H., Nishiyama, S., Hirono, O., Matsui, M., Sugawara, S., et al. (2014) · Journal of Cardiology · doi:10.1016/j.jjcc.2013.12.008 · Cited by 11
Effects of eicosapentaenoic acid and docosahexaenoic acid on lipoproteins in hypertriglyceridemia
Patel, A., & Budoff, M. J. (2016) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000233 · Cited by 11
Effects of Eicosapentaenoic Acid on Arterial Calcification
Saito, Y., Nakamura, K., & Ito, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155455 · Cited by 11
Yokoyama, Y., Kuno, T., Morita, S. X., Slipczuk, L. N., Takagi, H., Briasoulis, Α., Latib, A., Bangalore, S., & Heffron, S. P. (2022) · Journal of Cardiology · doi:10.1016/j.jjcc.2022.07.008 · Cited by 11
Arm and ankle blood pressure indices, and peripheral artery disease, and mortality: a cohort study
Mohammedi, K., Pigeyre, M., Bosch, J., Yusuf, S., & Gerstein, H. C. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae087 · Cited by 11
Rizos, E. C., & Elisaf, M. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.02.050 · Cited by 11
Losurdo, P., Grillo, A., Panizon, E., Zanetti, M., Bardelli, M., Biolo, G., Fabris, B., & Carretta, R. (2015) · Vascular Pharmacology · doi:10.1016/j.vph.2014.12.005 · Cited by 11
Fish in the Mediterranean diet
Molina‐Vega, M., Gómez‐Pérez, A. M., & Tinahones, F. J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818649-7.00025-4 · Cited by 11
Diretriz BRASPEN de Terapia Nutricional no Diabetes Mellitus
Campos, L. F., Borges, V. C., Barreto, P. A., González, M. C., Ceniccola, G. D., de Abreu, H. B., Alves, J. T. M., Segadilha, N. L. A. L., Kumbier, M. C. C., & Castro, M. G. (2020) · Braspen Journal · doi:10.37111/braspenj.diretrizdm2020 · Cited by 11
Morimoto, M., Lee, E. H., Zhang, X., Inaba, Y., Inoue, H., Ogawa, M., Shirasawa, T., Yokosuka, O., & Miki, T. (2016) · Nutrition and Diabetes · doi:10.1038/nutd.2016.21 · Cited by 11
Alzoubi, M. R., & Al-Domi, H. A. (2016) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2016.06.024 · Cited by 11
Kawasoe, S., Ide, K., Usui, T., Kubozono, T., Yoshifuku, S., Miyahara, H., Maenohara, S., Ohishi, M., & Kawakami, K. (2018) · Circulation Journal · doi:10.1253/circj.cj-18-0607 · Cited by 11
LDL, HDL, VLDL, and CVD Prevention: Lessons from Genetics?
Hewing, B., & Landmesser, U. (2015) · Current Cardiology Reports · doi:10.1007/s11886-015-0610-z · Cited by 11
Bolli, G. B., Consoli, A., & Giaccari, A. (2012) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2012.10.004 · Cited by 10
Diabetes and Lipids: A Review and Update on Lipid Biomarkers and Cardiovascular Risk
Tsushima, Y., & Hatipoğlu, B. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.03.011 · Cited by 11
Liu, F., & Cai, H. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1583267 · Cited by 10
Omega-3 fatty acids and the genetic risk of early onset acute coronary syndrome
Yinko, S. S. L. L., Thanassoulis, G., Stark, K. D., Tsadok, M. A., Engert, J. C., & Pilote, L. (2014) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2014.06.001 · Cited by 10
Luo, H., Zhao, M., Feng, X., Gao, X., Hong, M., Liu, M., Li, Y., Liu, W., Liu, Y., Yu, C., et al. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13469 · Cited by 10
Dose-response effects of omega-3 on platelet aggregation: an observational study
Kander, T., Lindblom, E., & Schött, U. (2018) · Journal of International Medical Research · doi:10.1177/0300060518789817 · Cited by 10
Omega-3 for the prevention of cardiovascular diseases: meta-analysis and trial-sequential analysis
Cabiddu, M., Russi, A., Appolloni, L., Mengato, D., & Chiumente, M. (2020) · European Journal of Hospital Pharmacy · doi:10.1136/ejhpharm-2020-002207 · Cited by 10
Kim, J., Hoang, T., Kim, J., Bu, S. Y., Choi, J., Park, E., Lee, S.-M., Park, E., Min, J. Y., Lee, I. S., et al. (2020) · Nutrients · doi:10.3390/nu12103203 · Cited by 10
Feingold, K. R. (2020) · Europe PMC (PubMed Central) · Cited by 10
Chan, D. C., Pang, J., & Watts, G. F. (2016) · Springer eBooks · doi:10.1007/978-3-319-11251-0_30 · Cited by 10
Zhang, J., Cai, A., Chen, G., Wang, X., Cai, M., Li, H., Nissen, S. E., Lip, G. Y. H., & Lin, H. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwac192 · Cited by 10
Imaging subclinical coronary atherosclerosis to guide lipid management, are we there yet?
Piña, P., Lorenzatti, D., Paula, R., Daich, J., Schenone, A. L., Gongora, C. A., Garcia, M. J., Blaha, M. J., Budoff, M. J., Berman, D. S., et al. (2022) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2022.100451 · Cited by 10
Monge, A., Harris, W. S., Ortiz‐Panozo, E., Yunes, E. M., Cantú-Brito, C. G., Catzín‐Kuhlmann, A., López‐Ridaura, R., & Lajous, M. (2016) · Journal of Nutrition · doi:10.3945/jn.115.227264 · Cited by 10
Lipoprotein Metabolism and the Treatment of Lipid Disorders
Freeman, M. W., & Walford, G. A. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00041-x · Cited by 10
Liu, W., Xie, X., Liu, M., Zhang, J., Liang, W., & Chen, X. (2018) · Scientific Reports · doi:10.1038/s41598-018-19193-5 · Cited by 10
Ihekweazu, C. (2021) · Health Communication · doi:10.1080/10410236.2021.1950291 · Cited by 10
Omega-3 fatty acids in the treatment of heart failure
Kelling, M., Dimza, M., Bartlett, A., Traktuev, D. O., Duarte, J. D., & Keeley, E. C. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102730 · Cited by 9
Tseng, P., Zeng, B., Hsu, C.-W., Liang, C., Stubbs, B., Chen, Y.-W., Chen, T., Lei, W., Chen, J.-J., Shiue, Y., et al. (2025) · Advances in Nutrition · doi:10.1016/j.advnut.2025.100366 · Cited by 9
Omega-3 Fatty Acids and Cardiovascular Disease: A Narrative Review for Pharmacists
Patel, D. K., & Busch, R. S. (2021) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484211023715 · Cited by 9
Dong, S., Wang, Y., Bian, J., Chen, H., Dong, J., Zhu, J., Zhang, T., Du, Q., & Zhao, R. (2024) · Nutrition Journal · doi:10.1186/s12937-024-01051-y · Cited by 9
Iyngkaran, P., & Thomas, M. C. (2016) · Health Care Current Reviews · doi:10.4172/hccr.1000106 · Cited by 9
Nyirenda, C. K., Kabagambe, E. K., Koethe, J. R., Kiage, J. N., Chi, B. H., Musonda, P., Blevins, M. L., Bosire, C. N., Tsai, M. Y., & Heimburger, D. C. (2015) · Journal of Nutrition and Metabolism · doi:10.1155/2015/635817 · Cited by 9
Shibata, M. C. (2013) · International Journal of Clinical Practice · doi:10.1111/ijcp.12232 · Cited by 9
Comparative cardiometabolic effects of fibrates and omega-3 fatty acids
Han, S. H., Oh, P. C., Lim, S. K., Eckel, R. H., & Koh, K. K. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.01.223 · Cited by 9
Sinning, D., Leistner, D. M., & Landmesser, U. (2016) · Herz · doi:10.1007/s00059-016-4430-8 · Cited by 9
Reprint of: Marine OMEGA-3 fatty acids in the prevention of cardiovascular disease
Mori, T. A. (2018) · Fitoterapia · doi:10.1016/j.fitote.2018.04.003 · Cited by 9
Assessing the Highest Level of Evidence from Randomized Controlled Trials in Omega-3 Research
Sahye‐Pudaruth, S., & David, W. L. (2023) · Nutrients · doi:10.3390/nu15041001 · Cited by 9
Tian, X., Chen, S., Wang, P., Zhang, Y., Zhang, X., Xu, Q., Wu, S., & Wang, A. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.029173 · Cited by 9
Revising common beliefs in the management of stable CAD
Ferrari, R. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2012.184 · Cited by 9
Zeng, Q., Dong, S.-Y., Liu, Y.-P., Fu, J. Q., Shuai, P., Zhao, Z., & Li, T.-X. (2017) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2017.09.004 · Cited by 9
Reducing Cardiovascular Disease Risk in Women Beyond Statin Therapy: New Insights 2020
Mosca, L. J., Návar, A. M., & WENGER, N. K. (2020) · Journal of Women s Health · doi:10.1089/jwh.2019.8189 · Cited by 9
Marine-derived n-3 fatty acids therapy for stroke
Campano, C. G. A., MacLeod, M. J., Aucott, L. S., & Thiès, F. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012815.pub2 · Cited by 9
Genetics of Coronary Atherosclerosis
Aragam, K. G., & Kathiresan, S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-42880-4.00003-0 · Cited by 9
Desnoyers, M., Kim, G., Madingou, N., Gagné, M.-A., Daneault, C., Rosiers, C. D., & Rousseau, G. (2018) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2018-0043 · Cited by 8
Collister, D., Rodrigues, J. C., Mbuagbaw, L. C. E., Devereaux, P. J., Guyatt, G. H., Herrington, W. G., & Walsh, M. W. (2020) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2020.09.035 · Cited by 8
Approach to patients with hypertriglyceridemia
Chait, A., & Feingold, K. R. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101659 · Cited by 8
Thyroid Dysfunction and Cardiovascular Events in Patients With Dysglycemia
Shah, R., Orlov, S., Paré, G., & Gerstein, H. C. (2023) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2023.01.007 · Cited by 8
Suzuki, A., Ando, H., Takashima, H., Kumagai, S., Kurita, A., Waseda, K., Suzuki, Y. A., Mizuno, T., Harada, K., Uetani, T., et al. (2014) · EuroIntervention · doi:10.4244/eijv10i7a138 · Cited by 8
DiNicolantonio, J. J., Meier, P., & O’Keefe, J. H. (2013) · Europe PMC (PubMed Central) · Cited by 8
Metadata
- Authors
- The ORIGIN Trial Investigators
- Corresponding author
- The ORIGIN Trial Investigators
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-07-26
- Volume
- 367
- Issue
- 4
- Pages
- 309-318
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1560062315
- Semantic Scholar
- 00cc8344ced92b3c8921b97df8607e6b3032e111
- Cited by
- 929
- References
- 21
- Citations by year
- 2026: 19 · 2025: 23 · 2024: 41 · 2023: 53 · 2022: 51 · 2021: 57 · 2020: 76 · 2019: 60 · 2018: 72 · 2017: 56 · 2016: 90 · 2015: 79 · 2014: 90 · 2013: 122 · 2012: 38
- FWCI
- 97.82
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Monash University Research Portal (Monash University) (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- HAL (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- IRIS (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Nutritional Studies and Diet
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- omega-3 fatty acids, cardiovascular outcomes, type 2 diabetes, dysglycemia, impaired fasting glucose, impaired glucose tolerance, insulin glargine, cardiovascular mortality, major vascular events, triglycerides, serum lipids, cardiac arrhythmias, cardiovascular risk reduction, dietary supplementation, omega-3 fatty acid ethyl esters
- MeSH terms
- Insulin Glargine, Aged, Cardiovascular Diseases, Cholesterol, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Hypoglycemic Agents, Male, Middle Aged, Triglycerides, Fatty Acids, Omega-3, Incidence, Proportional Hazards Models, Treatment Failure, Glucose Intolerance, Insulin, Long-Acting, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
